Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives
Recruitment status was: Not yet recruiting
Parkinson Disease is one of the most common neurodegenerative illnesses. First degree relatives of Parkinson patient are in high risk for developing the disease. We will try to detect early changes in brain metabolism before the appearance of Parkinson symptoms.
Participants: first degree relatives of diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes.
The examination results will be given to the participants by a doctor from the neurology department.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
Please refer to this study by its ClinicalTrials.gov identifier: NCT01089270
|Contact: Einat Even-sapir, PhD, MD||972-3-6974444 ext email@example.com|
|Contact: Ayelet Kurzband, BA||972-3-6974444 ext firstname.lastname@example.org|
|Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center||Not yet recruiting|
|Tel Aviv, Israel|
|Contact: Einat Even-Sapir, MD, PhD 972-3-6974444 ext 3536 Evensap@tasmc.health.gov.il|
|Contact: Ayelet Kurzband, BA 972-3-6974444 ext 3536 email@example.com|
|Sub-Investigator: Hedva Lerman, MD|
|Sub-Investigator: Nir Giladi, PhD, MD|
|Sub-Investigator: Anat Milerman|
|Principal Investigator:||Einat Even-Sapir, MD, PhD||Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|